Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 5, September-October, p. 749–755

Publication type: original article

Language: English

Factors Related to Microalbuminuria in Patients with Chronic Obstructive Pulmonary Disease

Erdal Kaysoydu1,A,B,D, Sulhattin Arslan1,A,C,F,G, Gürsel Yıldız2,A,B,C, Ferhan Candan3,A,G

1 Department of Chest Disease, Faculty of Medicine, Cumhuriyet University, Turkey

2 Department of Nephrology, Atatürk State Hospital, Turkey

3 Department of Nephrology, Faculty of Medicine, Cumhuriyet University, Turkey


Background. Chronic obstructive pulmonary disease (COPD) is characterized by inhaled particles and gases inducing chronic inflammation of the airways accompanied by a not fully reversible airflow limitation. Systemic inflammation has an important role in the pathogenesis of COPD. In parallel, several comorbidites can be observed. Microalbuminuria is related to endothelial dysfunction. Microalbuminuria was increased in exacerbation periods of COPD.
Objectives. The aim of the study was evaluate to the presence of microalbuminuria (MA) in patients with chronic obstructive pulmonary disease (COPD) and its relationship to inflammation, arterial blood gas parameters and 24-hour ambulatory blood pressure alterations.
Material and Methods. Seventy COPD patients and 40 healthy volunteers were enrolled in the study. 24-h ambulatory blood pressure monitoring (ABPM) results, including pressure and pulse rates of the subjects were recorded and the cases were classified as “dipper” if a normal fall of more than 10% in blood pressure was observed at night and “non-dipper” if not. Routine renal function tests were performed, C-reactive protein (CRP) values were examined and urine samples were obtained to scrutinize the presence of MA. Patients were allocated into two groups, those with and without MA. The spirometry and arterial blood gas results of the patients were recorded.
Results. The urinary albumin creatinin ratio (64.8 ± 91.8), CRP (21 ± 14.8), nocturnal systolic and diastolic blood pressure (118 ± 14 and 72 ± 10), nocturnal and diurnal pulse (87 ± 17 and 90 ± 14), nocturnal pulse pressure (49 ± 11), mean pulse (89 ± 15), mean pulse pressure (48 ± 10) and the number of non-dipper subjects (65) were found significantly higher in the COPD group than in the control group (10.6 ± 6, 5.4 ± 2.4, 105 ± 6 and 68 ± 7, 70 ± 10 and 78 ± 11, 42 ± 1, 75± 11, 42 ± 7 and 5, respectively); (p < 0.001, < 0.001, < 0.001 and 0.041, < 0.001 a nd < 0.001, < 0.001, < 0.001, < 0.001 and < 0.001, respectively). Nocturnal pulse (89 ± 17) and CRP (23.5 ± 14.8) were found to be significantly higher in COPD patients with MA than in COPD patients without MA (78 ± 8 and 8.8 ± 6.3, respectively); (p = 0.021 and < 0.001, respectively).
Conclusion. The facts that CRP, a systemic inflammation marker, and mean nocturnal pulse pressure values were significantly higher in the group with MA among COPD patients, and that ambulatory blood pressure values did not differ between COPD patients with and without MA, suggest both a possible role of inflammation in MA development in COPD patients and a relationship between MA and increased heart rate.

Key words

COPD, arterial blood gas, inflammation, microalbuminuria, non-dipper.

References (33)

  1. The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2013), the Pocket Guide (updated 2013). Available at:
  2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350, 2645–2653.
  3. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: Creactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175, 250–255.
  4. de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, AguirreJaime A, Celli BR, Casanova C: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27, 902–907.
  5. Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28, 1245–1257.
  6. Diercks GF, Van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH: The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 2002, 18, 525–535.
  7. Barr RG, Mesia-Vela S, Austin JH, Basner RC, Keller BM, Reeves AP, Shimbo D, Stevenson L: Impaired flowmediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 2007, 15, 176, 1200–1207.
  8. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. Hypertension 2005, 45, 198–202.
  9. Komurcuoglu A, Kalenci S, Kalenci D, Komurcuoglu B, Tibet G: Microalbuminuria in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 2003, 59, 269–272.
  10. Cogo A, Ciaccia A, Legorini C, Grimaldi A, Milani G: Proteinuria in COPD patients with and without respiratory failure. Chest 2003, 123, 652–653.
  11. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y: Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008, 26, 97–102.
  12. Seo WS, Oh HS: The circadian rhythms of blood pressure and heart rate in the hypertensive subjects: dippers and non-dippers. Yonsei Med J 2002, 43, 320–328.
  13. Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, Inenaga T, Kimura G: Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 1999, 33, 29–35.
  14. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Satoh H, Hisamichi S: Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997, 10, 1201–1207.
  15. Fagard RH, Van Den Broeke C, De Cort P: Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005, 19, 801–807.
  16. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y: Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006, 47, 149–154.
  17. Equiluz-Bruck S, Schnack C, Kopp HP, Scherntaner G: Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypertens 1996, 9, 1139–1143.
  18. Inaba M, Negishi K, Takahashi M, Serizawa N, Maruno Y, Takahashi K, Katayama S: Increased night:day blood pressure ratio in microalbuminuric normotensive NIDDM patients. Diabetes Res Clin Pract 1998, 40, 161–166.
  19. Agusti AG: COPD, a multicomponent disease: implications for management. Respir Med 2005, 99, 670–682.
  20. Casanova C, de Torres JP, Navarro J, Aguirre-Jaíme A, Toledo P, Cordoba E, Baz R, Celli BR: Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182, 1004–1010.
  21. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO, de Zeeuw D; PREVEND Study Group: C reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004, 43, 791–796.
  22. Phelps DT, Ferro TJ, Higgins PJ, Shankar R, Parker DM, Johnson A: TNF-alpha induces peroxynitrite-mediated depletion of lung endothelial glutathione via protein kinase C. Am J Physiol 1995, 269, 551–559.
  23. Forsblom CM, Groop PH, Ekstrand A, Tötterman KJ, Sane T, Saloranta C, Groop L: Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998, 21,1932–1938.
  24. Thoenes M, Reil JC, Khan BV, Bramlage P, Volpe M, Kirch W, Böhm M: Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag 2009, 5, 577–585.
  25. Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, Erdmann J, Schunkert H: Association of lowgrade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006, 21, 2780–2787.
  26. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005, 112, 969–975.
  27. Stewart AG, Bardsley PA, Baudouin SV, Waterhouse JC, Thompson JS, Morice AH, Howard P: Changes in atrial natriuretic peptide concentrations during intravenous saline infusion in hypoxic cor pulmonale. Thorax 1991, 46, 829–834.
  28. Peinado VI, Pizarro S, Barbera JA: Pulmonary vascular involvement in COPD. Chest 2008, 134, 808–814.
  29. Stamm AM, Meinerz G, Silva JC: Systemic hypertension and microalbuminuria. Arq Bras Cardiol 2007, 89, 415–420.
  30. Deferrari G, Pontremoli R: Microalbuminuria, hypertension and cardiovascular risk. Cardiologia 1994, 39, 159–162.
  31. Farasat SM, Valdes C, Shetty V, Muller DC, Egan JM, Metter EJ, Ferrucci L, Najjar SS: Is longitudinal pulse pressure a better predictor of 24-hour urinary albumin excretion than other indices of blood pressure? Hypertension 2010, 55, 415–421.
  32. Wang Y, Hu Y, Li Y, Li H, Chu S, Zhu D, Gao P: Association of renal function with the ambulatory arterial stiffness index and pulse pressure in hypertensive patients. Hypertens Res 2012, 35, 201–206.
  33. Kozan O, Ozcan EE, Sancaktar O, Kabakcı G: The prevalence of microalbuminuria and relevant cardiovascular risk factors in Turkish hypertensive patients. Arch Turk Soc Cardiol 2011, 39, 635–645.